AMD3100 inhibits naive T cell accumulation in the bone marrow of NOD mice. Prediabetic NOD mice (15–16 weeks of age) were treated with PBS or AMD3100 (AMD) daily for 8 days. Two hr after the last AMD3100 injection, mice were analyzed by flow cytometry. A, Comparison of percentage of CD4 and CD8 T cells (mean ± SD) in the bone marrow of AMD3100 (n = 4) and PBS (n = 6) treated NOD mice. * p < 0.05. B, Comparison of CD44 versus CD45RB profiles of TCR+CD4+ cells from AMD3100 (n = 4) and PBS (n = 6) treated NOD mice. The numbers indicate percentages of cells in the gated areas. The percentages (mean ± SE) of CD45RBhi CD44lo naïve T cells are 47.3 ± 10.9 for PBS-treated mice and 24.8 ± 3.2 for AMD3100-treated mice (p < 0.01).